Kite Pharma (KITE) Receiving Somewhat Favorable Press Coverage, Analysis Finds
Headlines about Kite Pharma (NASDAQ:KITE) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kite Pharma earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.2368092964806 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s analysis:
- Kite Pharma Buys Santa Monica Property (canyon-news.com)
- Bluebird Bio Up On Buyout Speculation After Celgene-Juno Deal (benzinga.com)
- Santa Monica R&D Building Sells to Kite Pharma for $135 Million – Los Angeles Business Journal (labusinessjournal.com)
- Muscle CAR? Celgene’s $9B offer for Juno starts pundits weighing traction (bioworld.com)
Kite Pharma (NASDAQ:KITE) remained flat at $$179.79 on Monday. The firm has a market capitalization of $10,280.00 and a P/E ratio of -26.06. Kite Pharma has a 52 week low of $39.82 and a 52 week high of $179.95.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/01/29/kite-pharma-kite-receiving-somewhat-favorable-press-coverage-analysis-finds.html.
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.